This clinical trial examines how well a new drug, **Vutiglabridin**, works and how safe it is for people with early Parkinson's disease. Parkinson's is a brain disorder that affects movement. This trial is **Phase 2a**, meaning it tests the drug on a small group of patients after initial trials on healthy people. The study is **randomized** and **double-blind**, so neither the participants nor the doctors know who gets the drug or a **placebo** (a harmless pill that looks like the drug). Participants will take one pill every day for **24 weeks**. Doctors will monitor their health through tests like ECGs (heart checks), blood tests, and physical exams to ensure the drug is safe. They will also check if the drug helps improve Parkinson's symptoms. **Key Points:** - The study lasts **24 weeks**, requiring regular visits for testing. - Participants must be **40 to 75 years old** and diagnosed with Parkinson's within the last two years. - Some health conditions or medications may exclude you from participating.